UNLABELLED: Glucokinase activators (GKAs) represent one of the leading hopes for the next generation of type 2 diabetes (T2D) therapeutics, showing efficacy in reducing blood glucose and HbA1c levels in animal models of T2D and short-term human trials. While the hypoglycaemic risks of GCK activation in pancreatic beta-cells have long been appreciated, the hepatic effects of GKAs have generally been perceived to be without significant side effect. In this issue of the British Journal of Pharma...Expand abstract
- Publisher copy:
- Copyright date:
Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?
If you are the owner of this record, you can report an update to it here: Report update to this record